Project Grant R01HL188164
Award Date 8/15/26
Completion Date 4/30/31
Dollars Obligated $463K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $769,846 on July 1, 2026, under Cardiovascular Diseases Research (CFDA 93.837), a Project Grant assistance type. The recipient will develop and apply an integrative genomics toolkit to characterize and engineer edits to regulatory DNA sequences with the goal of reprogramming gene expression for therapeutic applications. The toolkit combines computational models to predict how sequence changes to enhancers...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $768,912 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify and validate genetic variants associated with cardiac differentiation and congenital heart disease. The research integrates artificial intelligence with genome engineering to discover intrinsic gene regulatory networks governing heart development. Stanford will employ a base-resolution neural network...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $165,888 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decipher the genetic architecture of heart failure with preserved ejection fraction (HFPEF) and identify novel therapeutic targets. The recipient will enhance a machine learning model trained to predict HFPEF by incorporating cardiac MRIs and electrocardiograms, improving model specificity for genomic...
- The National Heart, Lung, and Blood Institute awarded the University of California Irvine $235,500 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine familial hypercholesterolemia prevalence, underdiagnosis, and undertreatment disparities in the United States. The recipient will analyze whole genome sequencing and electronic health record data to characterize the current state of familial hypercholesterolemia (FH) across demographic variables,...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $768,830 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune-fibroblast crosstalk in genetic dilated cardiomyopathy. The research integrates patient-specific induced pluripotent stem cells (iPSCs), three-dimensional cardiac organoids embedded in engineered disease-specific niches, CRISPR-based high-throughput screening, single-cell RNA sequencing,...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $1,541,206 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify druggable targets for cancer therapy-induced cardiotoxicity. The research characterizes proteasome inhibitor-induced cardiovascular toxicity through three aims. Aim 1 profiles cell type-specific cytotoxicity using patient-specific induced pluripotent stem cell-derived cardiomyocytes and endothelial...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $162,391 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define mechanisms of cardiovascular dysfunction in Down syndrome and identify therapeutic candidates. The research uses vascularized cardiac organoids derived from human pluripotent stem cells, integrated with single-cell multi-omics, high-throughput screening, and artificial intelligence-driven data mining to...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $333,197 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to design and pilot-test a community-engaged intervention aimed at reducing ultra-processed food consumption in toddlers aged two to three years to improve cardiovascular health. The research evaluates the association between ultra-processed food consumption and changes in adiposity, cardiometabolic risk...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $516,181 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a prospective observational ancillary study nested within the MIDAS (Milrinone for Prevention of Post-Ligation Cardiac Syndrome) clinical trial. The study uses non-invasive bedside monitoring techniques—near-infrared spectroscopy (NIRS), lung ultrasound (LUS), and targeted neonatal echocardiography...